Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment
NCT ID: NCT00288925
Last Updated: 2009-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
30 participants
INTERVENTIONAL
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma
NCT02117258
ZN-c3 + Gemcitabine in Pancreatic Cancer
NCT06015659
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
NCT00005926
Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
NCT04131192
Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer
NCT00710710
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Z-360
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* KPS \> 70%
* Life expectancy of at least 3 months
Exclusion Criteria
* received previous radiotherapy for the current indication
* Currently receiving chemotherapy
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zeria Pharmaceutical
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tim Meyer, PhD, MD
Role: PRINCIPAL_INVESTIGATOR
Royal Free Hospital NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Free Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01010106E
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.